JIUQUAN, China, Jan. 11, 2022 /PRNewswire/ -- Qilian
International Holding Group Limited (Nasdaq: QLI) (the "Company",
"Qilian International", "we", "our" or "us"), a China-based pharmaceutical and chemical
products manufacturer, today released a letter to shareholders from
the Chairman of the Company's board of directors.
Dear Shareholders,
As a well-established manufacturer with a long history in the
Chinese pharmaceuticals and chemical industry, the Company was
officially listed on Nasdaq Global Market ("Nasdaq") in
January 2021. The Company was the
first company to be headquartered in Gansu Province and the first company in the
oxytetracycline industry in China
to be listed in the U.S. The successful listing of the Company's
securities on Nasdaq may attract international investors' attention
and facilitate the Company's rapid business development. On the
first anniversary of the Company's listing on Nasdaq, on behalf of
the Company's Board of Directors, I would like to express my
sincere appreciation to all shareholders for their understanding,
trust, and support for the Company in the challenging year of
2021.
Qilian International has a large portfolio of products including
licorice products, oxytetracycline products, traditional Chinese
medicine derivatives product, heparin product, sausage casings, and
fertilizers. The Company maintains production facilities in Jiuquan
City of Gansu Province, Chengdu City of Sichuan Province, and Rugao
City of Jiangsu Province in China.
Each subsidiary has high production efficiency, the stable and
reliable product quality, and a nationwide marketing network. In
2021, we further strengthened our corporate governance and
optimized infrastructure to make sure the progress of our projects.
We have also expanded into new markets, and enhanced our brand
reputation and product recognition. Specifically, our achievements
in 2021 included: the listing of two of our brands, " Qilian
Shan®" and " Gan Di Xin®", on the List
for Development of Leading Enterprises with Large Varieties and
Brands of Pharmaceuticals of Gansu
Province; the entry into a new heparin sodium project;
completing the first phase of organic fertilizer development, which
has been commenced production; and the research and development of
nitrofurantoin enteric-coated tablets, vitacoenzyme, and
others.
We expect that 2022 will be an important year for Qilian
International to improve performance in the complex and changing
market. We will strive to overcome the impact of circumstances such
as the COVID-19 pandemic, economic downturn, increase in raw
material prices, and supply chain disruptions, While seeking
opportunities and maintaining stability in business operations, the
Company is set to explore its full potential to achieve the
expected goals. We will continue to increase the research and
development of nitrofurantoin enteric-coated tablets and
vitacoenzyme, raise technical and capital investment, accelerate
the research and development process, and bring the products to the
market as soon as possible to increase sales; Meanwhile, we
will complete the project of heparin sodium product that launched
in July 2021 in Chongqing and put it into production; We will
strive to grow our annual production and sales of fertilizers by
more than 20% year-on-year. In addition, we will set up a trading
company in Hainan Province to
expand our trading business and lay the foundation for opening up
international trade. Furthermore, the Company will also increase
publicity to improve brand awareness.
We will continue to carry forward the corporate core culture of
Qilian International and fully dedicated to growing and developing
our business and bringing value to all shareholders and
society.
We firmly believe that Qilian International's future goals will
be achieved.
Zhanchang Xin
Chairman and CEO
Qilian International Holding Group Limited
About Qilian International Holding Group Limited
Qilian International Holding Group Limited, headquartered
in Gansu, China, is a
pharmaceutical and chemical products manufacturer in China. It
focuses on the development, manufacture, marketing and sale of
licorice products, oxytetracycline products, traditional Chinese
medicine derivative products, heparin products, sausage casings,
and fertilizers. The Company's products are sold in more than 20
Provinces in China. For more information, visit the Company's
website
at http://ir.qlsyy.net/index.html or http://qilianinternational.com/.
Forward-Looking Statements
This announcement contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All statements other than statements
of historical fact in this announcement are forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, financial
needs and the successful construction of the pig by-product
processing project facility. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company's registration statement and in its
other filings with the SEC.
For more information, please contact:
Qilian International Holding Group Limited
Email: ir@qlsyy.net
Ascent Investors Relations LLC
Tina Xiao
President
Phone: 917-609-0333
Email: tina.xiao@ascent-ir.com
View original
content:https://www.prnewswire.com/news-releases/qilian-international-holding-group-limited-releases-2022-chairman-letter-301458067.html
SOURCE Qilian International Holding Group Limited